uniQure NV (QURE)

[chmcnfunds]

Uniqure NV (QURE) Earns “Buy” Rating from Chardan Capital

March 28th, 2016 - By Renee Johnson - 0 comments

Uniqure NV logoChardan Capital reaffirmed their buy rating on shares of Uniqure NV (NASDAQ:QURE) in a research report sent to investors on Wednesday morning, MarketBeat.com reports. They currently have a $40.00 price objective on the stock.

A number of other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Uniqure NV from a buy rating to a hold rating in a research report on Wednesday, November 25th. Cowen and Company restated a buy rating on shares of Uniqure NV in a research report on Monday, November 30th. Leerink Swann restated an outperform rating and issued a $48.00 price objective on shares of Uniqure NV in a research report on Friday, January 8th. Janney Montgomery Scott started coverage on shares of Uniqure NV in a research report on Monday, November 30th. They issued a buy rating and a $40.00 price objective for the company. Finally, Piper Jaffray restated an overweight rating and issued a $35.00 price objective on shares of Uniqure NV in a research report on Wednesday, January 6th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $40.36.

Uniqure NV (NASDAQ:QURE) opened at 11.95 on Wednesday. The firm’s market capitalization is $289.41 million. Uniqure NV has a one year low of $10.61 and a one year high of $36.38. The company has a 50 day moving average price of $13.92 and a 200-day moving average price of $18.07.

Several institutional investors have bought and sold shares of the company. Perceptive Advisors LLC increased its position in Uniqure NV by 40.1% in the fourth quarter. Perceptive Advisors LLC now owns 967,093 shares of the company’s stock worth $15,996,000 after buying an additional 276,824 shares in the last quarter. Eventide Asset Management LLC increased its stake in shares of Uniqure NV by 12.9% in the fourth quarter. Eventide Asset Management LLC now owns 174,900 shares of the company’s stock valued at $2,893,000 after buying an additional 20,000 shares during the period. Columbus Circle Investors increased its stake in shares of Uniqure NV by 493.7% in the fourth quarter. Columbus Circle Investors now owns 113,548 shares of the company’s stock valued at $1,878,000 after buying an additional 94,422 shares during the period. Deutsche Bank AG increased its stake in shares of Uniqure NV by 53.2% in the fourth quarter. Deutsche Bank AG now owns 112,088 shares of the company’s stock valued at $1,853,000 after buying an additional 38,943 shares during the period. Finally, Tocqueville Asset Management L.P. increased its stake in shares of Uniqure NV by 5.6% in the fourth quarter. Tocqueville Asset Management L.P. now owns 79,750 shares of the company’s stock valued at $1,319,000 after buying an additional 4,200 shares during the period.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
_________________________________________________
http://www.iramarketreport.com/uniqure-nv-qure-earns-buy-rating-from-chardan-capital/41523/

QURE